Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Current Assets (2016 - 2025)

Ultragenyx Pharmaceutical has reported Current Assets over the past 11 years, most recently at $951.0 million for Q4 2025.

  • Quarterly Current Assets rose 16.4% to $951.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $951.0 million through Dec 2025, up 16.4% year-over-year, with the annual reading at $951.0 million for FY2025, 16.4% up from the prior year.
  • Current Assets was $951.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $643.2 million in the prior quarter.
  • Over five years, Current Assets peaked at $1.1 billion in Q1 2021 and troughed at $596.0 million in Q1 2024.
  • The 5-year median for Current Assets is $783.0 million (2023), against an average of $799.8 million.
  • Year-over-year, Current Assets plummeted 40.83% in 2023 and then skyrocketed 37.39% in 2024.
  • A 5-year view of Current Assets shows it stood at $856.6 million in 2021, then rose by 3.19% to $883.9 million in 2022, then decreased by 17.16% to $732.2 million in 2023, then increased by 11.58% to $817.0 million in 2024, then grew by 16.4% to $951.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Current Assets are $951.0 million (Q4 2025), $643.2 million (Q3 2025), and $719.8 million (Q2 2025).